176 related articles for article (PubMed ID: 11442640)
1. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
[TBL] [Abstract][Full Text] [Related]
2. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
Scharrer I; Bray GL; Neutzling O
Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
[TBL] [Abstract][Full Text] [Related]
3. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
[TBL] [Abstract][Full Text] [Related]
4. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
ElAlfy MS; Tantawy AA; Ahmed MH; Abdin IA
Haemophilia; 2000 Nov; 6(6):635-8. PubMed ID: 11122388
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
6. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
Addiego J; Kasper C; Abildgaard C; Hilgartner M; Lusher J; Glader B; Aledort L
Lancet; 1993 Aug; 342(8869):462-4. PubMed ID: 8102429
[TBL] [Abstract][Full Text] [Related]
7. Incidence of inhibitors in haemophiliacs. A review of the literature.
Scharrer I; Neutzling O
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
[TBL] [Abstract][Full Text] [Related]
9. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
10. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
[TBL] [Abstract][Full Text] [Related]
11. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
[TBL] [Abstract][Full Text] [Related]
13. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
[TBL] [Abstract][Full Text] [Related]
17. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
18. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003.
Blatny J; Komrska V; Blazek B; Penka M; Ovesna P;
Blood Coagul Fibrinolysis; 2015 Sep; 26(6):673-8. PubMed ID: 25886834
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.
Rocino A; Papa ML; Salerno E; Capasso F; Miraglia E; de Biasi R
Haemophilia; 2001 Jan; 7(1):33-8. PubMed ID: 11136378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
